dc.contributor.author | Micha, A | |
dc.contributor.author | Parvaiz, MA | |
dc.contributor.author | O'Riordan, L | |
dc.contributor.author | MacNeill, F | |
dc.contributor.author | Rusby, JE | |
dc.date.accessioned | 2022-05-04T14:10:59Z | |
dc.date.available | 2022-05-04T14:10:59Z | |
dc.identifier.citation | Clinical breast cancer, 2022 | en |
dc.identifier.issn | 1526-8209 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5112 | |
dc.identifier.eissn | 1938-0666 | en_US |
dc.identifier.eissn | 1938-0666 | |
dc.identifier.doi | 10.1016/j.clbc.2022.02.012 | en_US |
dc.identifier.doi | 10.1016/j.clbc.2022.02.012 | |
dc.description.abstract | <h4>Aims</h4>Isotope and blue dye dual localization in sentinel lymph node biopsy (SLNB) gives localization rates of over 98% and is the recommended technique. However blue dye risks a range of adverse reactions. Since 2010, for clinically node negative disease, we have only used blue dye if there is no clear isotope signal at surgery.<h4>Methods</h4>Electronic records of patients who underwent isotope-only SLN localization between July 2010 and April 2012 were examined. Data were collected on localization and oncological outcomes.<h4>Results</h4>426 patients were included. Isotope-only localization rate was 97.4% (415/426). The median follow-up was 63.5 months (IQR: 60.7-70.9). Median age was 57 (IQR: 48-67). Median SLN yield was 2 (range: 1-5). Axillary recurrence rate was 1.4% with median time to recurrence of 39.3 months. In-breast recurrence, distant disease and contralateral breast cancer rates were 2.8%, 7%, and 1.9% respectively and 15 (3.5%) patients died of metastatic breast cancer.<h4>Conclusion</h4>Isotope-only SLNB has a comparable localization rate to dual isotope/blue dye SLNB and can spare the risk of blue dye adverse reactions. The low axillary recurrence rate, maintained to more than 5 years, confirms that isotope-only SLNB is a feasible and safe alternative to dual blue dye/isotope localization. | en_US |
dc.format | Print-Electronic | en_US |
dc.language | eng | en_US |
dc.language.iso | eng | en |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | en |
dc.title | Isotope-Only Localization for Sentinel Lymph Node Biopsy - Medium-Term Oncological Outcomes. | en |
dc.type | Journal Article | |
dcterms.dateAccepted | 2022-02-25 | |
rioxxterms.version | VoR | en |
rioxxterms.versionofrecord | 10.1016/j.clbc.2022.02.012 | en |
dc.relation.isPartOf | Clinical breast cancer | en_US |
pubs.notes | Not known | en_US |
pubs.organisational-group | /ICR | |
pubs.publication-status | Published | en_US |
pubs.embargo.terms | Not known | en_US |
dc.contributor.icrauthor | Rusby, Jennifer | |